Leap Therapeutics Announces Collaboration With EORTC to Evaluate DKN-01 in Combination with PD-L1 Cancer Immunotherapy and ...
CAMBRIDGE, Mass., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced an immunotherapy collaboration with the European Organisation for …